PMID- 34808366
OWN - NLM
STAT- MEDLINE
DCOM- 20220322
LR  - 20220322
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 175
DP  - 2022 Jan
TI  - Efficacy of artemisinin and its derivatives in animal models of type 2 diabetes 
      mellitus: A systematic review and meta-analysis.
PG  - 105994
LID - S1043-6618(21)00578-8 [pii]
LID - 10.1016/j.phrs.2021.105994 [doi]
AB  - Although current evidence suggests that artemisinin and its derivatives play a 
      multitarget therapeutic role in type 2 diabetes mellitus (T2DM), their efficacy 
      and safety remain under debate. This meta-analysis aimed to evaluate the effects 
      and safety of artemisinin and its derivatives in T2DM animal models. Preclinical 
      studies that met the inclusion criteria were retrieved from PubMed, Embase, Web 
      of Science, Scopus, CINAHL, OpenGrey, Google Scholar, Psyclnfo, British Library 
      Ethos, ProQuest Dissertations & Theses, China National Knowledge Internet, VIP 
      Information Chinese Periodical Service Platform, Chinese Biomedicine Literature 
      Database, and Wanfang Data Knowledge Service Platform. Twenty-two studies 
      involving 526 animals were included in the meta-analysis. The RevMan 5.3 and 
      Stata 15.0, were used to perform the statistical analyses. The overall results 
      showed that artemisinin or its derivatives could significantly reduce fasting 
      plasma glucose, 2-h plasma glucose (2hPG) in the intraperitoneal glucose 
      tolerance test (IPGTT), 2hPG in the intraperitoneal insulin tolerance test 
      (IPITT), glycated hemoglobin A1c, under the curve in the IPGTT/IPITT, total 
      cholesterol, triglyceride, low-density lipoprotein cholesterol, free fatty acid, 
      and urine volume. Although increase in body weight was observed due to 
      administration of the compounds, no significant effect was observed regarding 
      serum insulin. In terms of adverse reactions, only two of the included studies 
      reported that high-dose artemether may cause digestive inhibition in mice. Our 
      results suggest that artemisinins could improve several parameters related to 
      glycolipid metabolism in T2DM animal models. However, to evaluate the 
      antidiabetic effects and safety of artemisinins in a more accurate manner, 
      additional preclinical studies are necessary.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Wu, Tingchao
AU  - Wu T
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 
      China. Electronic address: 513025801@qq.com.
FAU - Feng, Haoyue
AU  - Feng H
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 
      China. Electronic address: fenghaoyue@stu.cdutcm.edu.cn.
FAU - He, Mingmin
AU  - He M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 
      China. Electronic address: 279549910@qq.com.
FAU - Yue, Rensong
AU  - Yue R
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 
      China. Electronic address: songrenyue@cdutcm.edu.cn.
FAU - Wu, Shaoqi
AU  - Wu S
AD  - Ningxia Medical University, Yinchuan, Ningxia, China. Electronic address: 
      597750884@qq.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20211119
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Artemisinins)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Animals
MH  - Artemisinins/*therapeutic use
MH  - Diabetes Mellitus, Experimental/*drug therapy
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Animal models
OT  - Artemether (PubChem CID: 68911)
OT  - Artemisinin
OT  - Artemisinin (PubChem CID: 68827)
OT  - Artemisinin derivatives
OT  - Artesunate (PubChem CID: 6917864)
OT  - Meta-analysis
OT  - Type 2 diabetes mellitus
EDAT- 2021/11/23 06:00
MHDA- 2022/03/23 06:00
CRDT- 2021/11/22 20:17
PHST- 2021/09/12 00:00 [received]
PHST- 2021/11/08 00:00 [revised]
PHST- 2021/11/18 00:00 [accepted]
PHST- 2021/11/23 06:00 [pubmed]
PHST- 2022/03/23 06:00 [medline]
PHST- 2021/11/22 20:17 [entrez]
AID - S1043-6618(21)00578-8 [pii]
AID - 10.1016/j.phrs.2021.105994 [doi]
PST - ppublish
SO  - Pharmacol Res. 2022 Jan;175:105994. doi: 10.1016/j.phrs.2021.105994. Epub 2021 
      Nov 19.